CIK 1602263
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2019-Q3. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Unclassified | 40.27% | 14 |
| Life Sciences Tools & Services | 35.91% | 1 |
| Pharmaceuticals & Biotechnology | 23.82% | 5 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | TXG | 10x Genomics, Inc. | Health Care | 35.91% |
| 2 | AXSM | Axsome Therapeutics, Inc. | Health Care | 21.42% |
| 3 | CONSTELLATION PHARMACEUTICALS INC. | Unclassified | 18.64% | |
| 4 | BIOHAVEN PHARMACTL HLDG CO L | Unclassified | 6.64% | |
| 5 | SHOCKWAVE MED INC | Unclassified | 3.34% | |
| 6 | IVERIC BIO INC | Unclassified | 2.27% | |
| 7 | KALVISTA PHARMACEUTICALS INC | Unclassified | 1.72% | |
| 8 | OBSEVA SA | Unclassified | 1.58% | |
| 9 | MERSANA THERAPEUTICS INC COM | Unclassified | 1.39% | |
| 10 | SPRO | SPERO THERAPEUTICS INC | Unclassified | 1.20% |
6/20 names classified · sector 59.7% of weight · industry 59.7% · mkt cap 59.7%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 59.7% of the book is sector-classified (unclassified names shown, never dropped).
Only 0% of book weight classified — the grid is NOT representative of the whole book.
Classified: 0.0% of book weight (0/8 names) · unclassified 100.0%: , TXG, AXSM, SPRO, RLMD, MIST, NXTC, PTGX. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | TXG10X GENOMICS INC | 1,786,431 | $136M | 35.9% | HOLD |
| 2 | AXSMAXSOME THERAPEUTICS INC. | 785,981 | $81M | 21.4% | TRIM −12% |
| 3 | CONSTELLATION PHARMACEUTICALS INC. | 1,500,631 | $71M | 18.6% | ADD 107% |
| 4 | BIOHAVEN PHARMACTL HLDG CO L | 462,903 | $25M | 6.6% | TRIM −35% |
| 5 | SHOCKWAVE MED INC | 288,838 | $13M | 3.3% | TRIM −55% |
| 6 | IVERIC BIO INC | 1,004,299 | $9M | 2.3% | NEW |
| 7 | KALVISTA PHARMACEUTICALS INC | 366,268 | $7M | 1.7% | TRIM −3% |
| 8 | OBSEVA SA | 1,573,639 | $6M | 1.6% | TRIM −30% |
| 9 | MERSANA THERAPEUTICS INC COM | 922,514 | $5M | 1.4% | NEW |
| 10 | SPROSPERO THERAPEUTICS INC | 474,015 | $5M | 1.2% | HOLD |
| 11 | RLMDRELMADA THERAPEUTICS INC | 114,876 | $4M | 1.2% | NEW |
| 12 | Adverum Biotechnologies, Inc. | 383,620 | $4M | 1.2% | NEW |
| 13 | MARINUS PHARMACEUTICALS INC | 1,486,676 | $3M | 0.8% | HOLD |
| 14 | FORTY SEVEN INC | 77,714 | $3M | 0.8% | NEW |
| 15 | MISTMILESTONE PHARMACEUTICALS IN | 148,560 | $2M | 0.6% | HOLD |
| 16 | NXTCNEXTCURE INC | 36,249 | $2M | 0.5% | NEW |
| 17 | MYOVANT SCIENCES LTD | 76,768 | $1M | 0.3% | NEW |
| 18 | 89BIO INC | 41,235 | $1M | 0.3% | NEW |
| 19 | BELLEROPHON THERAPEUTICS INC | 659,087 | $230,000 | 0.1% | TRIM −84% |
| 20 | PTGXPROTAGONIST THERAPEUTICS INC | 32,211 | $227,000 | 0.1% | TRIM −92% |
Where this firm's principals came from and which firms its alumni went on to found.
